Cue Biopharma Appoints Lucinda Warren Interim CEO to Drive CUE-401 Clinic Entry
Lucinda Warren, Cue Biopharma’s chief financial and business officer since February 2026, has been named interim president and CEO after Usman Azam’s departure effective March 26, 2026. The board highlights her deals securing CUE-401 rights and collaborations with Boehringer Ingelheim, aiming to advance CUE-401 into the clinic in H2 2026.
1. Leadership Transition
On March 26, 2026, Usman Azam stepped down as president, CEO and director of Cue Biopharma. The board appointed Lucinda Warren—who joined as chief business officer in September 2024 and became CFO in February 2026—as interim president and CEO to steer the company through its next growth phase.
2. Deal Execution Track Record
Warren led the return of worldwide development and commercialization rights for CUE-401, closed the Boehringer Ingelheim collaboration for CUE-501, and secured a strategic license agreement with ImmunoScape to develop a cell therapy for solid tumors, demonstrating a strong record in business development.
3. Pipeline Advancement Strategy
As interim CEO, Warren plans to move CUE-401—a bifunctional molecule combining a TGF-beta mask and IL-2 mutein—into clinical trials by the second half of 2026, while exploring additional partnerships to enhance the company’s value and expand its Immuno-STAT® platform.